Description

Zupanib Tablets (Pazopanib Tablets) – Product Description Zupanib Tablets contain Pazopanib, a prescription targeted anti-cancer medicine used to treat advanced renal cell carcinoma (RCC) and advanced soft tissue sarcoma (STS). It belongs to the tyrosine kinase inhibitor (TKI) class and works by blocking multiple enzymes involved in tumor growth and the formation of new blood vessels (angiogenesis), helping slow the progression of cancer. Zupanib is taken orally once daily, usually on an empty stomach, exactly as prescribed by the treating oncologist. It may be used as a single-agent therapy depending on the patient's diagnosis and treatment plan. Active Ingredient Pazopanib Dosage Form Oral Tablets Therapeutic Indications Advanced Renal Cell Carcinoma (Kidney Cancer) Advanced Soft Tissue Sarcoma (STS) Other approved oncology indications as determined by the treating oncologist How It Works Pazopanib inhibits multiple tyrosine kinase receptors, including VEGFR, PDGFR, and c-KIT, reducing the formation of new blood vessels that supply tumors with oxygen and nutrients. This helps inhibit tumor growth and spread. Key Features Targeted therapy for advanced kidney cancer and soft tissue sarcoma Multi-targeted kinase inhibitor with anti-angiogenic activity Convenient once-daily oral tablet May help slow disease progression in eligible patients Manufactured according to stringent pharmaceutical quality standards Storage Store below 30°C in a cool, dry place. Protect from moisture and direct sunlight. Keep out of reach of children. Note: Zupanib Tablets (Pazopanib) are prescription-only medicines and should be used only under the supervision of a qualified oncologist. Regular monitoring of liver function, blood pressure, thyroid function, and overall clinical status is recommended during treatment.